# OnCo record odronextamab (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/odronextamab/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "odronextamab" ;
  schema:name "Odronextamab"@en ;
  schema:description "Odronextamab is Regeneron's CD20 bispecific, approved in Europe for lymphoma and in the US for follicular lymphoma after earlier FDA rejections over confirmatory-trial enrolment."@en ;
  schema:url <https://onco.cc/drugs/odronextamab/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Odronextamab> ;
  onco:status "approved" ;
  onco:modality "Bispecific T-cell engager (CD20×CD3)" ;
  schema:alternateName "Lynozyfic (EU: Ordspono)" ;
  onco:approval "EU 2024: R/R DLBCL and follicular lymphoma after ≥2 lines (conditional)", "US 2025: R/R follicular lymphoma after ≥2 lines (accelerated)" ;
  onco:cancers <https://onco.cc/cancers/dlbcl/> ;
  onco:technologies <https://onco.cc/technologies/t-cell-engager/> ;
  onco:targets <https://onco.cc/targets/cd20/>, <https://onco.cc/targets/cd3/> ;
  onco:companies <https://onco.cc/companies/regeneron/> ;
  onco:trials <https://onco.cc/trials/nct06097364/>, <https://onco.cc/trials/nct06149286/>, <https://onco.cc/trials/nct06230224/>, <https://onco.cc/trials/nct06091865/>, <https://onco.cc/trials/nct06091254/>, <https://onco.cc/trials/nct03888105/> .